Acceleron Announces Sotatercept Achieved Primary and Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Patients with Pulmonary Arterial Hypertension

The PULSAR trial achieved its primary endpoint: a statistically significant reduction in pulmonary vascular resistance The trial also achieved statistically significant improvements in the key secondary endpoint of six-minute walk distance (6MWD) and other secondary endpoints, including amino-terminal brain natriuretic…

Continue reading »

Working with the NIHR/Wellcome Trust Imperial CRF- Partnerships in Clinical Trials

Working with the NIHR/Wellcome Trust Imperial CRF-Partnerships in Clinical Trials The Imperial CRF held an industry engagement event on the 19th January 2017 to promote future collaborations with commercial partners. The event included presentations from CRF staff, Imperial PIs, Industry…

Continue reading »